Philadelphia Had the Rankings. Now It Doesn't Even Have Those.

Philadelphia spent 2025 collecting good news about its technology sector. PitchBook ranked the region tenth among the world's venture capital ecosystems, a list dominated almost entirely by metros with vastly larger economies. Startup Genome placed it thirteenth globally in its 2025 report. The local venture trade group, the Philadelphia Alliance for Capital and Technologies, reported that the region now accounts for 3.2 percent of all U.S. deal activity, up from 2 percent a decade ago. By the metrics cities use in press releases, Philadelphia's tech sector looked to be ascending.

Then Startup Genome released its 2026 Global Startup Ecosystem Report, and Philadelphia posted the single worst decline of any ecosystem in the global top 40. The city fell twenty spots, from 13th to 33rd, a steeper drop than any of the other 39 ecosystems on the list experienced in either direction. For comparison, Seattle climbed five spots into the top ten. Austin jumped twelve places to 18th. Dallas moved up eleven to 27th. Philadelphia's fall wasn't part of a broader regional reshuffling, it was an outlier even among American cities that are supposedly competing in the same tier.

That ranking, and the dollar figures underneath it, now tell the same story. The gap between Philadelphia's reputation and its fundamentals isn't a tension to be managed anymore. It's a trend, and it's the most important thing happening in Philadelphia tech right now.

What the new ranking actually measures

Startup Genome's methodology matters here, because it shows the decline wasn't a fluke of survey timing. The ranking scores ecosystems on six factors: Performance, Funding, Market Reach, Talent and Experience, an AI-Native Cluster factor, and an R&D Engine. Funding is explicitly graded on access to early-stage capital and on "Quality & Activity," meaning the number of local investors, how experienced they are, and what share of them were actively deploying capital in 2025. The AI-Native Cluster factor measures the ratio of AI startups to all tech startups, the share of seed funding going to AI companies, and Series A funding volume specifically in AI. Philadelphia's diversified, healthcare-and-life-sciences-weighted startup base, the thing PACT's own report calls a strength, is close to a structural mismatch with a scoring system built around AI funding concentration and a deep local investor bench.

The global numbers behind that AI-Native factor explain why the mismatch is getting worse rather than better. Late-stage funding into AI-Native companies more than doubled in 2025 to $108 billion, over half of all late-stage venture funding globally, and AI-Native exit value jumped over 500 percent year over year. North America's share of global late-stage funding climbed to 64 percent, up from 56 percent in 2021, but that capital is overwhelmingly concentrated in two places: North American startups captured 73 percent of early-stage and 86 percent of late-stage global AI funding, with Silicon Valley and Beijing absorbing most of it. Philadelphia, a city PACT credits for healthcare AI deal share roughly tripling year over year, is still a rounding error in a category where the rest of the country is also a rounding error next to the Bay Area.

That single-year ranking collapse lines up with everything the dollar figures already show.

The dollar figures underneath the ranking

Start with venture capital, the resource that determines whether a startup hires its next ten engineers in Philadelphia or somewhere else. PACT's 2025 Venture Report put total regional VC investment at $3.8 billion across 470 deals, a decline in both dollars and deal count from 2024. Pittsburgh, a metro roughly a quarter of Philadelphia's population, brought in $1.48 billion in 2025, its strongest year since 2019, and closed more than twice the venture capital per capita that Philadelphia did. Boston pulled in over $15 billion. New York topped $7 billion in 2025 alone, on top of $28.5 billion in 2024, more than Boston, Los Angeles, and Philadelphia combined.

The pattern holds in Philadelphia's strongest sector. The region's life sciences and biotech base is genuinely world class, built on a density of universities, hospitals, and a cell and gene therapy industry that has few rivals nationally. But Genetic Engineering & Biotechnology News' 2025 ranking of U.S. biopharma clusters placed Philadelphia seventh, down a spot from the year before, after Los Angeles overtook it on the strength of venture investment alone. Philadelphia biotech companies raised $656 million in 2024 and just $236 million in the first half of 2025. Boston and San Francisco each routinely raise $5 billion to $7 billion a year in the same category. The report's own framing was direct: Philadelphia has the science, the talent, and the infrastructure, but capital is what converts research into companies, and that's where the region keeps coming up short.

This is not a story about Philadelphia producing less. Tech employment in the city has grown faster than the regional population for years. The "brain drain" framing that dogged Philadelphia for two decades is, by most measures, over. Campus Philly's data shows the city now retains young, college-educated residents at rates that outpace Washington, Boston, and Seattle, with the population of degree-holding 25-to-34-year-olds up 155 percent since 2000. The talent is staying. The capital isn't following it at the same rate.

Why the money behaves differently than the people

Part of the answer is structural and dates back further than this cycle. Philadelphia has never built a deep bench of large, locally headquartered venture firms that can write the big late-stage checks PitchBook and CB Insights track when they rank cities. First Round Capital, founded by Josh Kopelman, is still routinely described as the only venture firm of national stature with Philadelphia roots, and it has since opened offices in San Francisco and New York alongside its Philadelphia presence. When the city wanted to seed a public-private investment fund a decade ago, it turned to Kopelman's firm because there wasn't a deep field of alternatives. That fund, StartUp PHL, was meaningful at the time. It was also a $3 million initial commitment, a rounding error against what Boston or Pittsburgh allocate through their venture ecosystems in a single deal.

The current AI-driven funding boom has made the gap more visible rather than less. Nationally, venture funding surged 46 percent year over year in 2025, concentrated overwhelmingly in AI infrastructure and large-language-model companies clustered in the Bay Area, with California alone pulling in 64 percent of all U.S. venture dollars. Philadelphia's strength is the opposite shape: diversified, weighted toward healthcare, life sciences, and enterprise software, sectors PACT's own report credits for steady, boom-resistant growth, but precisely the categories that the AI surge has not flowed into at the same scale. PACT's president, Dean Miller, has argued that Philadelphia's reliance on outside capital, namely investors from the Bay Area and New York who back local companies without relocating them, is itself a sign of the region's credibility. That may be true. It's also a description of a city that exports its return on investment to wherever those funds are headquartered.

Two rankings, two stories, one set of facts

It's worth being precise about what's still true. PitchBook's ranking, the one that put Philadelphia at tenth globally, weights growth over a six-year window as heavily as absolute scale, and Philadelphia scored seventh in growth on that basis. That's a real number, and it reflects real progress from where the region stood a decade ago. It is also a number that's easier to post when you're growing from a smaller base, and it measures a different thing than Startup Genome's 2026 ranking, which is built around current-year funding access, local investor depth, and AI-Native cluster strength, the categories where Philadelphia is now falling behind in absolute terms, not just relative ones.

Both rankings can be accurate and still point in different directions, because they're measuring different time horizons with different weights. But when the forward-looking measure, the one built on this year's funding data and this year's AI concentration, shows the steepest single-year collapse of any global ecosystem, it stops being reasonable to lean on the backward-looking growth score as the headline. Pittsburgh's per-capita lead, Boston's $15 billion year, the widening gap GEN identified in biotech, and now a twenty-spot fall in the most comprehensive global ranking are no longer four separate data points. They're the same trend line measured four different ways.

What would actually move the number

The fixes that get discussed locally, talent attraction campaigns, lifestyle marketing, convention center bookings tied to this year's America 250 commemorations and World Cup matches, address a problem the city has already solved. Philadelphia doesn't have a people problem. It has a check-writing problem, and the institutions capable of solving it are the ones that can underwrite a $50 million Series C without a partner in San Francisco signing off first.

That likely means a combination of things the city hasn't fully committed to: public pension and endowment capital allocated specifically to local growth-stage funds, the way Pittsburgh's university and foundation money has quietly backed its venture resurgence; a deliberate strategy to grow a second and third Philadelphia-headquartered fund with the scale to lead, not just follow, late-stage rounds; and an honest acknowledgment from civic boosters that a six-year growth score and a twenty-spot single-year fall can both be true at once. Philadelphia's tech sector has earned the right to stop being compared to its 2010 self. It hasn't yet earned the right to stop being compared to Boston.